TPNL 0.490   +0.075 +18.10% Updated: 07-08-2017 $TPNL

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
105
TPNL 0.490   +0.075 +18.10% Updated: 07-08-2017 $TPNL
Last Trade: 7/7/2017 2:08:00 PM
Last 0.490   +0.075 +18.10%
Open 0.445
Previous Close 0.415
Day High / Low 0.490 / 0.445
Year High / Low 0.490 / 0.150
Volume 230,483
Projected Volume 230483 (315%)
# of Trades / Projected 20 / 20
Dividend / Yield - / -
Abnormal Activity ABNORMAL DAY UP
Abnormal Volume ABNORMAL VOLUME
Gap NONE
Candle BULLISH
Volatility Today HIGH
Volatility Yesterday MEDIUM
Price Relativity
From 40 Day High 100%
From 80 Day High 100%
From 150 Day High 100%
From 40 Day Low 122%
From 80 Day Low 126%
From 150 Day Low 165%
Pivot Analysis
Price Pivot $ 0.470
Day Resistance 1 $ 0.500
Day Support 1 $ 0.460
Day Resistance 2 $ 0.520
Day Support 2 $ 0.430
Consolidations
Short Term YES
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 73,198
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 41,486
Today / 150 Day Avg Vol ABOVE
Abnormal Volume ABNORMAL VOLUME
William Volume Accumulation bullish
Volume Price Trend bullish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bullish
100 Day Trend bullish
Stochastics neutral
RSI bearish
MACD bearish
Moving Average Indictors
15 Day Trend bullish
45 Day Trend bullish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? ABNORMAL DAY UP
Volatility Index Today HIGH
Volatility Index Yesterday MEDIUM
10 Day Volatility DECREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Celltrion's ZYMFENTRA Shows Efficacy in Crohn's Disease Study

Updated Category News Views 203

Celltrion's ZYMFENTRA® Demonstrates Efficacy in Crohn's Disease Celltrion, Inc. has recently published promising results from a post-hoc analysis of the LIBERTY-CD study regarding ZYMFENTRA® (infliximab-dyyb). This analysis reveals significant findings about the efficacy of ZYMFENTRA in treating Crohn's disease (CD), regardless of disease location, and it's exciting...

Continue Reading
Akamai Hits Major Milestone with FedRAMP High Ready Status

Updated Category News Views 232

Akamai Cloud Achieves FedRAMP High Ready Status CAMBRIDGE, Mass. – Akamai Technologies, Inc. (NASDAQ: AKAM), a leader in cybersecurity and cloud computing, has proudly announced its recent achievement of the FedRAMP High Ready status. This vital milestone confirms that Akamai is fully prepared to offer federal agencies cloud services that comply with the most rigorous...

Continue Reading
Sam Bankman-Fried's Letter: Claims, Allegations, and Future Hopes

Updated Category News Views 161

Sam Bankman-Fried's Explosive Revelations About FTX In a recently penned letter, former FTX founder Sam Bankman-Fried expressed a firm belief that FTX was never truly insolvent. He attributed much of the downfall of what he called a "$136 billion enterprise" to mismanagement by attorneys, laying blame for the financial struggles on those who were supposed to provide legal...

Continue Reading
Kraus Hamdani Aerospace's K1000ULE Unveils New Heights in UAVs

Updated Category News Views 151

Kraus Hamdani Aerospace's K1000ULE Achieves Remarkable Milestone Kraus Hamdani Aerospace, an innovator in autonomy and AI-driven unmanned systems, has announced the inclusion of its K1000ULE UAS in the U.S. Department of Defense's trusted Blue UAS Cleared List and Select List. This recognition marks a significant achievement in the field of unmanned aerial vehicles,...

Continue Reading
VNA & PACS Market Set to Reach $7.92 Billion by 2030

Updated Category News Views 280

Understanding the Vendor Neutral Archive (VNA) & PACS Market Growth The Vendor Neutral Archive (VNA) and Picture Archiving and Communication System (PACS) market is entering an exciting growth phase. This market, valued at approximately US$4.62 billion recently, is predicted to experience a significant uptick as it is forecasted to expand at a remarkable compound annual...

Continue Reading